Wilson Sonsini Goodrich & Rosati represented Dewpoint Therapeutics in the transaction. Dewpoint Therapeutics Inc., the leading biotechnology company that develops therapeutics by targeting biomolecular condensates, announced...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Saniona in the transaction. Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, announced a partnership with Acadia Pharmaceuticals (Acadia) for the...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Pure Lithium on the transaction. Pure Lithium Corporation, a disruptive Boston-based vertically integrated lithium metal battery technology company, announced the...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Ochre Bio in the transaction. Ochre Bio, a pioneer in chronic liver disease medicine development, announced the start of a...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Rubedo Life Sciences on the transaction. Rubedo Life Sciences (Rubedo), a biopharmaceutical company, announced it closed a $40M Series A...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Tempo Therapeutics in the transaction. Tempo Therapeutics, Inc. (“Tempo”) announced the completion of a $12 million Series A equity financing round, led by...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Arena BioWorks on patent and transactional matters. Arena BioWorks announced its launch as a biomedical research institute with a mission...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Ji Xing Pharmaceuticals Limited (JIXING) on the transaction. TMS Co., Ltd. (TMS) and Ji Xing Pharmaceuticals Limited (JIXING) announced that...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised C4 Therapeutics on the transaction. C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC) announced that it has entered into an exclusive license...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised JURA Bio on both the financing transaction and the collaboration agreement. JURA Bio announced a research collaboration with Syena, a cell...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Delve Bio in the transaction. Delve Bio announced it has debuted with $35 million in Series A financing led by Perceptive...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised Zymeworks on the deal. Zymeworks BC Inc. and Jazz Pharmaceuticals Ireland Ltd. announced that they entered into an exclusive license agreement to develop...
You must be a Standard 1 Year member to access this content.
